+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Radiotherapy Drug Market by Indication (Bone Metastasis, Liver Cancer, Neuroendocrine Tumors), Mechanism Of Action (Radioimmunotherapy, Radioligand Therapy), Radionuclide Type, End User - Global Forecast 2025-2030- Product Image
Targeted Radiotherapy Drug Market by Indication (Bone Metastasis, Liver Cancer, Neuroendocrine Tumors), Mechanism Of Action (Radioimmunotherapy, Radioligand Therapy), Radionuclide Type, End User - Global Forecast 2025-2030- Product Image
New

Targeted Radiotherapy Drug Market by Indication (Bone Metastasis, Liver Cancer, Neuroendocrine Tumors), Mechanism Of Action (Radioimmunotherapy, Radioligand Therapy), Radionuclide Type, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6142099
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Pioneering Precision Oncology: Unveiling the Strategic Emergence of Targeted Radiotherapy Drugs Transforming Cancer Treatment Landscapes Worldwide

The landscape of oncology treatment is undergoing a paradigm shift as targeted radiotherapy drugs emerge as pivotal tools in the precision medicine arsenal. These innovative therapies employ radioactive isotopes to deliver cytotoxic energy with exceptional accuracy, sparing healthy tissue and enhancing efficacy. In recent years, research breakthroughs have fueled the translation of novel radiopharmaceuticals from bench to bedside, elevating patient outcomes and redefining clinical protocols. Precision targeting of metastatic lesions has minimized collateral damage and reduced systemic toxicity, ushering in a new era of personalized cancer care.

Furthermore, advancements in molecular imaging and theranostic approaches have strengthened the synergy between diagnosis and treatment planning. By integrating diagnostic radionuclides with therapeutic counterparts, clinicians can achieve real-time monitoring of drug delivery and treatment response. This convergence of imaging and therapy underscores the potential of targeted radiotherapy drugs to revolutionize treatment algorithms, drive patient-centric decision-making, and foster collaborative research across multidisciplinary teams.

Dynamic Innovations and Regulatory Evolutions Reshaping the Landscape of Targeted Radiotherapy Drug Development and Clinical Adoption Across Oncology Practice

Rapid technological innovations and evolving regulatory frameworks are orchestrating transformative shifts in the targeted radiotherapy drug sector. Cutting-edge ligand engineering has improved the specificity of radioconjugates, enabling robust binding to tumor-associated antigens while minimizing off-target effects. Concurrently, developments in isotope production infrastructure and radioisotope purification techniques have enhanced supply reliability, reducing manufacturing bottlenecks and improving accessibility across global markets.

On the regulatory front, agencies have demonstrated greater flexibility in expediting approvals for radiopharmaceuticals, reflecting a recognition of their life-saving potential. Conditional pathways and breakthrough designations have shortened development timelines, encouraging strategic collaborations between biotech firms and academic research centers. At the same time, enhanced safety guidelines and standardized dosimetry protocols are shaping best practices, ensuring consistent clinical outcomes. Altogether, these dynamic innovations and policy advancements are fostering a fertile environment for sustained growth and continuous improvement in targeted radiotherapy applications.

Navigating the Impact of the 2025 United States Tariff Regime on Targeted Radiotherapy Drug Supply Chains and Cross Border Clinical Integration Strategies

The introduction of new tariffs on critical raw materials and radiolabeled compounds in 2025 has compelled stakeholders in the targeted radiotherapy drug ecosystem to reevaluate their supply chain strategies. Increased duties on precursor chemicals and shipping services have elevated manufacturing costs, prompting companies to explore alternative sourcing partnerships and localized production hubs. As a result, some manufacturers have established regional radiopharmacies to mitigate transit delays and ensure timely delivery of short-lived isotopes.

Moreover, cross-border clinical trial operations have encountered logistical complexities due to increased customs scrutiny and higher import fees. Sponsors are responding by adopting just-in-time inventory models and forging strategic alliances with contract manufacturing organizations in tariff-favorable jurisdictions. Despite these headwinds, the sector remains resilient, with innovators leveraging digital platforms to optimize procurement planning and maintain uninterrupted access to essential radiotherapy agents across international treatment centers.

Strategic Dissection of Indications Mechanisms Radionuclide Types and Care Settings Illuminating Nuanced Segmentation Trends in Targeted Radiotherapy Advances

Dissecting the market through multiple lenses reveals pivotal segmentation trends that inform strategic decision-making. Across indications such as bone metastasis, liver cancer, neuroendocrine tumors, and prostate cancer - including both metastatic castration resistant and metastatic hormone sensitive forms - developers are tailoring radioligands to exploit specific tumor biology. Early successes in neuroendocrine tumor targeting have accelerated interest in expanding peptide receptor radionuclide therapies to other solid tumors.

In terms of mechanism of action, distinctions between radioimmunotherapy and radioligand therapy continue to shape pipeline portfolios. Within radioimmunotherapy, alpha radioimmunoconjugates offer high-linear energy transfer cell kill, while beta counterparts provide deeper tissue penetration. Radioligand therapy innovations span peptide receptor radionuclide therapy and PSMA-targeted approaches, each demonstrating unique efficacy profiles. Meanwhile, the choice between alpha emitters like actinium-225 or radium-223 and beta emitters such as lutetium-177 or yttrium-90 is informed by tumor size, receptor density, and dosimetry requirements. Finally, the end-user spectrum - encompassing ambulatory surgical centers, dedicated cancer treatment facilities, and hospitals - is evolving to accommodate radiopharmacy integration and specialized administration protocols, reflecting a shift toward more decentralized delivery models.

Unveiling Regional Dynamics Shaping Targeted Radiotherapy Drug Uptake Across the Americas Europe Middle East Africa and Asia Pacific Landscapes

Regional dynamics are exerting significant influence on the adoption trajectory of targeted radiotherapy drugs. In the Americas, robust research infrastructures and supportive reimbursement frameworks have accelerated clinical uptake, with key academic centers pioneering theranostic trials. Cross-border partnerships within North America and Latin America are fostering knowledge exchange, while initiatives focused on radiopharmacy accreditation are ensuring consistent quality standards.

Across Europe, the Middle East, and Africa, harmonization of regulatory guidelines has facilitated multicountry clinical programs, although variations in reimbursement policies and infrastructure readiness persist. Government-led investments in nuclear medicine capabilities and public-private collaborations are gradually expanding access beyond established oncology hubs. Meanwhile, Asia-Pacific markets are characterized by dynamic growth driven by rising cancer incidence and government incentives for domestic isotope manufacturing. Localized production capacity, coupled with strategic alliances between global sponsors and regional biotech firms, is shaping a more resilient supply network and fostering innovation centers across emerging economies.

Examining the Competitive Footprint and Strategic Collaborations of Leading Biotech and Pharmaceutical Innovators Driving the Targeted Radiotherapy Drug Market

Leading entities in the targeted radiotherapy arena are forging competitive partnerships and investing heavily in pipeline diversification. Prominent pharmaceutical companies are acquiring specialized biotech startups to integrate novel radioligand platforms alongside established oncology franchises. Simultaneously, niche radiopharmaceutical developers are entering strategic licensing agreements to leverage larger organizations’ clinical trial expertise and commercial channels. Collaborative networks encompassing academic research centers, contract research organizations, and industry partners are accelerating first-in-class and best-in-class molecule development.

Furthermore, technology providers specializing in isotope separation and automated synthesis modules are expanding their service portfolios to meet increasing demand for customized radioconjugate production. Joint ventures between isotopic suppliers and manufacturing facilities are enhancing capacity for both alpha and beta emitters. These alliances underscore a collective commitment to overcoming technical and logistical challenges, ensuring that groundbreaking targeted radiotherapy options reach patients efficiently and safely.

Empowering Industry Stakeholders with Actionable Strategies to Accelerate Innovation Collaboration and Growth in the Targeted Radiotherapy Drug Ecosystem

Industry leaders should prioritize the establishment of integrated radiopharmacy networks that combine advanced nuclide production with modular synthesis technologies, ensuring agility in isotope supply and rapid response to clinical demand. Building cross-disciplinary teams that include nuclear medicine physicians, radiochemists, and data scientists will foster innovation in dosimetry modeling and patient-specific treatment planning. Additionally, forming consortiums with academic institutions to co-fund exploratory theranostic studies can accelerate the identification of novel targets and streamline regulatory submissions.

Strategic investment in digital platforms for logistics tracking and predictive supply chain analytics will enable organizations to navigate evolving tariff landscapes and reduce waste associated with short half-lives. Furthermore, engaging with payers and policymakers early in development cycles to demonstrate real-world evidence of clinical utility can enhance reimbursement alignment. By adopting these actionable measures, stakeholders can fortify their competitive positioning, enhance operational resilience, and deliver next-generation targeted radiotherapy solutions to patients more effectively.

Detailing the Rigorous Multidimensional Research Framework Data Sources and Analytical Techniques Underpinning the Targeted Radiotherapy Drug Market Study

This study was conducted using a robust research framework combining both primary and secondary methodologies. Secondary research encompassed an extensive review of peer-reviewed journals, clinical trial registries, regulatory filings, and patent databases to map technological advancements and competitive landscapes. Primary research involved in-depth interviews with key opinion leaders, including nuclear medicine specialists, radiochemists, and executive stakeholders across pharmaceutical and biotech organizations.

Quantitative data were validated through triangulation across multiple sources, ensuring consistency and reliability. Advanced analytical techniques, such as scenario analysis and sensitivity testing, were employed to assess the impact of regulatory shifts and tariff changes on supply chain dynamics. Findings were peer-reviewed by an advisory panel of external experts to uphold methodological rigor and mitigate potential biases. This comprehensive approach has yielded actionable insights that reflect the current state and future trajectories of the targeted radiotherapy drug domain.

Conclusive Perspectives on the Evolution Challenges and Strategic Imperatives Guiding the Future Trajectory of Targeted Radiotherapy Drug Innovations

The convergence of scientific innovation, regulatory adaptation, and strategic collaboration is propelling targeted radiotherapy drugs into a new era of precision oncology. As developers refine ligand designs and optimize isotope selection, the potential to address previously intractable tumor types expands. Despite geopolitical and logistical complexities, adaptive supply chain strategies and harmonized regulatory frameworks are facilitating broader access to these transformative treatments.

Looking ahead, sustained momentum will depend on continued cross-sector partnerships, real-world evidence generation, and alignment with value-based care models. By embracing these imperatives, stakeholders can navigate emerging challenges and deliver impactful radiotherapy solutions that improve patient outcomes and redefine standards of care in the fight against cancer.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Bone Metastasis
    • Liver Cancer
    • Neuroendocrine Tumors
    • Prostate Cancer
      • Metastatic Castration Resistant Prostate Cancer
      • Metastatic Hormone Sensitive Prostate Cancer
  • Mechanism Of Action
    • Radioimmunotherapy
      • Alpha Radioimmunoconjugates
      • Beta Radioimmunoconjugates
    • Radioligand Therapy
      • Peptide Receptor Radionuclide Therapy
      • Psma Radioligand Therapy
  • Radionuclide Type
    • Alpha Emitters
      • Actinium 225
      • Radium 223
    • Beta Emitters
      • Lutetium 177
      • Yttrium 90
  • End User
    • Ambulatory Surgical Centers
    • Cancer Treatment Centers
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Novartis AG
  • Bayer AG
  • Telix Pharmaceuticals Limited
  • Lantheus Holdings, Inc.
  • RayzeBio, Inc.
  • Actinium Pharmaceuticals, Inc.
  • ITM Isotope Technologies Munich SE
  • Curium SAS
  • Nordion Inc.
  • Advanced Accelerator Applications SA

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid expansion of lutetium-177 radiopharmaceutical production capacity in response to growing clinical demand
5.2. Increasing partnerships between biotech firms and academic centers for novel alpha-emitter targeted therapy development
5.3. Emergence of precision dosimetry software solutions integrating radiomics and artificial intelligence algorithms
5.4. Regulatory acceleration of theranostic agents through breakthrough designations and priority review pathways
5.5. Rising investment in CAR-T combined with radioconjugates for enhanced hematologic cancer treatment efficacy
5.6. Expansion of personalized treatment protocols for neuroendocrine tumors using targeted radioligand therapy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted Radiotherapy Drug Market, by Indication
8.1. Introduction
8.2. Bone Metastasis
8.3. Liver Cancer
8.4. Neuroendocrine Tumors
8.5. Prostate Cancer
8.5.1. Metastatic Castration Resistant Prostate Cancer
8.5.2. Metastatic Hormone Sensitive Prostate Cancer
9. Targeted Radiotherapy Drug Market, by Mechanism Of Action
9.1. Introduction
9.2. Radioimmunotherapy
9.2.1. Alpha Radioimmunoconjugates
9.2.2. Beta Radioimmunoconjugates
9.3. Radioligand Therapy
9.3.1. Peptide Receptor Radionuclide Therapy
9.3.2. Psma Radioligand Therapy
10. Targeted Radiotherapy Drug Market, by Radionuclide Type
10.1. Introduction
10.2. Alpha Emitters
10.2.1. Actinium 225
10.2.2. Radium 223
10.3. Beta Emitters
10.3.1. Lutetium 177
10.3.2. Yttrium 90
11. Targeted Radiotherapy Drug Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Cancer Treatment Centers
11.4. Hospitals
12. Americas Targeted Radiotherapy Drug Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Targeted Radiotherapy Drug Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Targeted Radiotherapy Drug Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Novartis AG
15.3.2. Bayer AG
15.3.3. Telix Pharmaceuticals Limited
15.3.4. Lantheus Holdings, Inc.
15.3.5. RayzeBio, Inc.
15.3.6. Actinium Pharmaceuticals, Inc.
15.3.7. ITM Isotope Technologies Munich SE
15.3.8. Curium SAS
15.3.9. Nordion Inc.
15.3.10. Advanced Accelerator Applications SA
16. Research AI17. Research Statistics18. Research Contacts19. Research Articles20. Appendix
List of Figures
FIGURE 1. TARGETED RADIOTHERAPY DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. TARGETED RADIOTHERAPY DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. TARGETED RADIOTHERAPY DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. TARGETED RADIOTHERAPY DRUG MARKET: RESEARCHAI
FIGURE 24. TARGETED RADIOTHERAPY DRUG MARKET: RESEARCHSTATISTICS
FIGURE 25. TARGETED RADIOTHERAPY DRUG MARKET: RESEARCHCONTACTS
FIGURE 26. TARGETED RADIOTHERAPY DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TARGETED RADIOTHERAPY DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BONE METASTASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BONE METASTASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY METASTATIC CASTRATION RESISTANT PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY METASTATIC CASTRATION RESISTANT PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY METASTATIC HORMONE SENSITIVE PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY METASTATIC HORMONE SENSITIVE PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA RADIOIMMUNOCONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA RADIOIMMUNOCONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA RADIOIMMUNOCONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA RADIOIMMUNOCONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PSMA RADIOLIGAND THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PSMA RADIOLIGAND THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ACTINIUM 225, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ACTINIUM 225, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIUM 223, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIUM 223, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY LUTETIUM 177, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY LUTETIUM 177, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY YTTRIUM 90, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY YTTRIUM 90, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 109. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 112. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 113. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 114. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 115. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 116. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 117. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 118. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 119. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 120. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 121. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 122. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 123. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 124. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 125. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 130. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 131. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 132. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 133. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 134. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 135. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 136. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 137. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 138. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 139. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 140. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 141. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 222. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 223. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 226. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 227. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 228. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 229. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 230. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 231. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 232. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 233. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 234. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 235. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 240. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 241. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 242. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 243. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 244. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 245. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 246. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 247. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 248. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 249. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 250. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 251. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 252. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 253. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 275. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 276. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 277. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 278. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 279. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 280. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 281. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 282. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 283. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 284. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 285. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 286. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 287. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 288. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 289. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 294. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 295. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 296. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 297. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 298. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 299. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 300. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 301. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 302. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 303. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 304. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 305. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 306. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 307. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Targeted Radiotherapy Drug Market report include:
  • Novartis AG
  • Bayer AG
  • Telix Pharmaceuticals Limited
  • Lantheus Holdings, Inc.
  • RayzeBio, Inc.
  • Actinium Pharmaceuticals, Inc.
  • ITM Isotope Technologies Munich SE
  • Curium SAS
  • Nordion Inc.
  • Advanced Accelerator Applications SA

Related Topics

Related Reports

Alpha Emitter - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Alpha Emitter - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 115 Pages
  • Global
From
Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Radiotherapy Global Market Report 2025 - Product Image

Radiotherapy Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Radiotherapy/Radiation Oncology Devices - Market Insights, Competitive Landscape, and Market Forecast -2030 - Product Image

Radiotherapy/Radiation Oncology Devices - Market Insights, Competitive Landscape, and Market Forecast -2030

  • Report
  • 150 Pages
  • Global
From
Radiotherapy Induced Oral Mucositis Treatment Global Market Report 2025 - Product Image

Radiotherapy Induced Oral Mucositis Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.